All In Biotech

Drug Trial Radar · NCT05169515

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

121

Planned (sponsor's estimate)

Start

Oct 26, 2022

Primary completion

Apr 30, 2029

Study completion Apr 30, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.

Conditions

  • Non-Hodgkin Lymphoma

Interventions

  • SC MosunetuzumabDrug

    Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)

  • IV GlofitamabDrug

    Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)

  • IberdomideDrug

    Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)

  • GolcadomideDrug

    Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)

  • ObinutuzumabDrug

    Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)

  • TocilizumabDrug

    Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with dose-limiting toxicities (DLTs) [dose escalation]Time frame: Until 90 days after the final dose of study treatment
  2. Percentage of participants with adverse events [all cohorts]Time frame: Until 90 days after the final dose of study treatment
  3. Best overall response rate (ORR), defined as the proportion of participants whose best overall response is a partial response (PR) or a complete response (CR) during the study, as determined by the investigator using Lugano 2014 criteria [dose expansion]Time frame: Up to 2 years after start of primary study treatment
  4. Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose escalation]Time frame: Until 90 days after the final dose of study treatment

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Moffitt Cancer Center

    Tampa, Florida

  • The University of Chicago

    Chicago, Illinois

  • Levine Cancer Institute

    Charlotte, North Carolina

  • UT MD Anderson Cancer Center

    Houston, Texas

  • Soroka

    Beersheba, Israel

  • Rambam Health Care Campus

    Haifa, Israel

  • Hadassah University Hospital - Ein Kerem

    Jerusalem, Israel

  • Center Hospital

    Ramat Gan, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • IRCCS Azienda Ospedaliero Universitaria di Bologna

    Bologna, Emilia-Romagna, Italy

  • IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"

    Meldola, Emilia-Romagna, Italy

  • Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chia

    Pisa, Piedmont, Italy

  • Hospital Universitari Vall d Hebron

    Barcelona, Spain

  • Clinica Universidad de Navarra-Madrid

    Madrid, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • Hosp Universitario Salamanca

    Salamanca, Spain

  • ICO L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario La Fe

    Valencia, Valencia, Spain

  • NHS Greater Glasgow and Clyde

    Glasgow, United Kingdom

  • University College London Hospitals

    London, United Kingdom

  • Nottingham University Hospitals City Campus

    Nottingham, United Kingdom

  • Oxford University Hospitals NHS Trust - Churchill Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.